Wall Street Reacts to Leadership Uncertainty in Biopharma Approvals
The resignation of Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research (CBER), sent biotech stocks tumbling on Monday, as investors worried about the future of regulatory approvals in the sector.
Marks, who played a key role in approving COVID-19 and RSV vaccines, cited concerns over the anti-vaccine stance of Health and Human Services Secretary Robert F. Kennedy Jr. and the ability of the new FDA head, Marty Makary, to resist such influences. His departure, effective April 5, has created uncertainty about the agency’s regulatory flexibility and future drug approvals.
Vaccine stocks were hit hardest, with Moderna (MRNA) plunging more than 10% in early trading. Novavax (NVAX) dropped over 8%, BioNTech (BNTX) fell more than 7%, while Dynavax (DVAX) and Vaxcyte (PCVX) declined 2% and 54%, respectively. Broader biotech losses included Gilead Sciences (GILD), which initially fell over 4% before recovering some ground.
Wall Street analysts warned of heightened risks for rare disease and cell and gene therapy companies, given their reliance on FDA support for novel product approvals. Jefferies analyst Michael Yee noted that concerns over Marks’s resignation had already driven biotech stocks down more than 20% year-to-date.
Despite the market reaction, some strategists, including Mizuho’s Jared Holz, cautioned against assuming the worst, suggesting that while Marks’s exit raises concerns, the broader impact on biotech innovation remains uncertain.
With the FDA’s transparency in question, investors are now watching closely for news on Marks’s successor and how the regulatory landscape will evolve under new leadership.
You might like this article:Bitcoin, MicroStrategy, and Coinbase: Strong Buying Opportunities Amid the Dip
